ANNUAL REPORT FY2024 7 Nyrada’s TRPC channel-blocking technology originated from the work of UNSW Sydney Prof. Gary Housley (Chair of Nyrada’s scientific advisory board) and Dr. Jasneet Parmar (Nyrada’s neuroscientist). Over the past ten years, Prof. Housley and Dr. Parmar have diligently developed key insights into TRPC channel inhibitors and their neurological implications. Their work included significant research on TRPC channels using mouse knockout models, focusing on how TRPC channels 3, 6, and 7 play a critical role in calcium dysregulation in neurons and glial cells. Prof. Housley’s and Dr. Parmar’s research has shown that blocking these channels can mitigate excitotoxicity and reduce brain injury expansion, signalling their potential as therapeutic targets for neuroprotection. Notably, TRPC channel-blocking therapy is not limited to neurological conditions. Other researchers have published promising data related to other therapeutic areas where TRPC channels play an important role, including cardio and pulmonary diseases, autoimmune disorders, and cancer. Nyrada’s Novel Neuroprotection Drug As part of Nyrada’s development process, our scientific team developed a broad portfolio of drug candidates that proved effective in animal models. Ultimately, NYR-BI03 was selected as our lead candidate due to its safety profile and fit for our clinical path forward in neurological applications. In February 2024, the Company reported the results from a preclinical stroke study that showed NYR-BI03 provided a statistically significant level of neuroprotection, rescuing 42% of brain injury in the penumbra region in treated animals. This was a significant result that paved the way for the Company to commence safety and tolerability studies on the path to a firstin-human Phase I clinical trial for NYR-BI03. We are very excited about these safety and tolerability studies because if we can prove NYR-BI03 is safe in humans, we then progress to Phase II studies and test for efficacy, with the potential to expand our pipeline to other TRPCrelated diseases where there is unmet or underserved clinical need. Targeting Large Unserved Market NYR-BI03 is targeting a very large and growing market in both TBI and stroke. There are no current FDA-approved therapies for TBI, which is experienced by over 70 million1 people worldwide each year. The estimated annual healthcare cost of non-fatal TBIs is over US$40 billion2 in the US alone. Approximately 15 million3 people globally suffer strokes, of whom 5 million are left permanently disabled. A recent inflection has been the massive investment in the US in clinical trial infrastructure to support the assessment of drugs like ours. The Track TBI Network is a research initiative focused on improving the understanding, diagnosis, and treatment of TBI. It spans 18 Level 1 Trauma Centres across the US and seeks to facilitate the conduct of TBI clinical trials. 1. https://pubmed.ncbi.nlm.nih.gov/33947273/ 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026675/ 3. https://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/index.html
RkJQdWJsaXNoZXIy MjE2NDg3